We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMatteo Goldey
Modified over 2 years ago
Downward Trends in Traditional Sourcing Markets and the Rise of Pharmerging Markets Kate Kuhrt CPhI Virtual Experience October 2010 © Thomson Reuters 2010
Agenda Key drivers of sourcing decisions –Quality –Cost Evolution of various sourcing markets Predictions about the future © Thomson Reuters 2010
About Thomson Reuters Generics & API Intelligence 20 years experience in tracking API manufacturing and generics An industry pioneer in research and analysis of global API manufacturing activity Develop and market the Newport database family More than 300 customers and 3,000 users across 43 countries in the Innovator, Generic, OTC and API manufacturing industries Serving the needs of –Business Development & Licensing Professionals –Portfolio Selection Teams –R&D and Regulatory Specialists –API Sourcing Specialists Team based in Portland, Maine, USA © Thomson Reuters 2010
Many Drivers of Sourcing Decisions, Including… Capabilities Capacity Quality Speed Relationships Cost Regulations Risk PR © Thomson Reuters 2010
World generic API manufacturing landscape Experience in supplying regulated markets Source: Newport Premium © Thomson Reuters 2010
Of the 400+ experienced manufacturers… Close to 1/3 are located in India and China Only 160 are pure API players Source: Newport Premium © Thomson Reuters 2010
Comparing Indian API Manufacturer Ratings, 2006 to 2010 Source: Newport Premium © Thomson Reuters 2010
Comparing Chinese API Manufacturer Ratings, 2006 to 2010 Source: Newport Premium © Thomson Reuters 2010
Comparing Italian API Manufacturer Ratings, 2006 to 2010 Source: Newport Premium © Thomson Reuters 2010
Challenges in the European API Sourcing Market Constraining SPCs in Italy introduced in 1991 No Bolar provisions until 2006 Reluctance to change Expensive labor Environmental controls © Thomson Reuters 2010
Drivers for India as a Major API Sourcing Destination No product patents until 2005 Cost advantage Rich talent pool No language barrier Improving IP protection Large and increasing number of FDA approved facilities © Thomson Reuters 2010
Drivers for China as a Major API Sourcing Destination Rich talent pool Leadership in certain product classes over India –Fermentation-based APIs –Steroid APIs –Intermediates –Base chemicals Cost advantage Improving IP and anti-counterfeiting environment Better infrastructure than India Government support for R&D © Thomson Reuters 2010
US DMF Filings (1999 – 2009) Source: Newport Premium © Thomson Reuters 2010
FDA Inspections of API Manufacturers (2001 – 2009) Source: Newport Premium © Thomson Reuters 2010
Progression of Indian Manufacturers Domestic FD, API WW API WW Formulation CRAMS NDDS NCE CostRisk Source: Piramal Investor Presentation 2008 © Thomson Reuters 2010
Total ANDA Approvals by Indian Generics Source: Newport Premium © Thomson Reuters 2010
US ANDAs belonging to Chinese companies Only 3 companies with final ANDA approvals All approved ANDAs have been acquired –Zhejiang Huahai (Huahai US Inc) ANDAs for 5 products acquired from Kali, KV, Par, Actavis Nevirapine tentative approval under PEPFAR –Beijing Pharmaceutical (Beijing Double Crane) ANDAs for 2 products acquired from Ranbaxy –Yabao Pharma Group (Beijing Yabao) ANDAs for 2 products acquired from Par and Ivax © Thomson Reuters 2010
Challenges in Indian and Chinese Sourcing Markets: Cost Cost TypeChinaIndiaEuropeU.S. Labor $ $$$$ Environmental$$$$$$ Energy$$ $$ IP Protection$$ cGMP Monitoring $$$$$$$ © Thomson Reuters 2010
Additional Challenges in Indian and Chinese Sourcing Markets Language barrier in China Inadequate infrastructure in India Uneven enforcement of rules in China Possibility of fraud Long-distance management Lack of senior level talent in top level management, QA, IP protection Focus on quick targets rather than long-term opportunities Cultural differences © Thomson Reuters 2010
Looking Ahead ? © Thomson Reuters 2010
Will Manufacturing Move to the 2 nd Wave Emerging Markets? Little experience with regulated markets Small API industry Limited Dose capabilities No indications of significantly better price at acceptable quality than in India or China © Thomson Reuters 2010
Whats Next for India? Increased emphasis on FD for regulated markets Increased CRAMS business Greater reliance on China for APIs and advanced intermediates Increased costs as Chinese materials become more expensive © Thomson Reuters 2010
Whats Next for China? Strengthened SFDA oversight Greater EHS, waste treatment enforcement Increased costs of labor Improvements in quality, technical packages, IP Additional companies will expand into finished dose for regulated markets Many companies will stay focused on local market © Thomson Reuters 2010
Whats Next for Europe? Benefitting from increased focus on reliability and quality in Europe, US, Brazil Focus on niche products (high potency, peptides, controlled substances) and biopharmaceuticals Innovative technologies Global production facilities and strategic relationships Forward integration into dose Further consolidation © Thomson Reuters 2010
Thank You! Kate Kuhrt Director, Generics and API Intelligence Thomson Reuters +1 207 871 9700 x26 email@example.com © Thomson Reuters 2010
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
DAVID HARDING CPhI 2008 SHANGHAI JUNE 24–26, 2008 Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success.
DAVID HARDING MARCH 12, 2008 DCAT WEEK PERCEPTIONS vs. REALITY Facts and Figures on the Generic Industry.
Lupin Press Meet, October 7, 2003 Lupin Press Meet October 7, 2003.
Identifying And Exploiting API Opportunities Across Emerging Markets API SOURCING STRATEGIES 2008 BERLIN, GERMANY DAVID HARDING NOVEMBER 24, 2008.
Developments, Trends and Implications for Executive Development June 2010 Nice, France.
Hale & Tempest Moving Beyond the Commodity Market: What Future is there in added Value Generics, Niche Products and Biosimilars? Dr. Brian W Tempest
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
Pharmaceuticals Limited India – CIS International Pharma Conference 3-5 th March 2006, Mumbai Prashant Nagre Vice President – API Division.
APIs for Regulated Market Generics: Whither Europe?
Pharma & Healthcare Logistics Development Roadmap for Luxembourg T h e r e i s s o m e t h i n g g o i n g o n i n L u x e m b o u r g ! T A S T r u s.
Threats and Opportunities for the Generic Industry KATE KUHRT JUNE 2006.
China Healthcare Consulting Inc. Creating Value for Our Clients Boston Healthcare Associates, Inc. 75 Federal Street, 9 th Floor.
Corporate Presentation INDOCO REMEDIES LTD. About Us Indian Company with an International presence Turnover 09-10; Rs Crores Among the fastest.
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest Shanghai, China 18 November 2011.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Indian Pharma Industry - At The Helm
Veiovis LifeSciences Pvt Ltd
PADMIN BUCH IPR Innovation & Global Market
ABLE LABORATORIES, INC.. Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements or other written.
Investor Presentation1 Creating Lasting Value Investor Presentation June 2009.
STRATEGIC MANAGEMENT 1 Irina Raynaud Pierre Jean Tessier Nicolas Cabrit Clément Tumoine.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Global Anti Counterfeit Packaging market for Food and Pharmaceuticals- Technologies & Global Markets (2009 to 2014) Markets & Markets – Analyst Briefing.
Mylan Laboratories Inc. (MYL) Solomon Lee, Analyst Graduation Date: April 2008.
Los Angeles Transportation Club May 14, 2013 Scott Satterlee C.H. Robinson Senior Vice President.
1 Enterprise and Global Management of Information Technology.
2015 Market Research Report on Global Water and Wastewater Treatment Chemicals Industry Published: Jan 2015 Single User License: US$ 2600 Corporate User.
How does FM in NZ compare to the UK and US?. looking back 20 years.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Turning the change of Globalisation into an Opportunity Understand reality then make reality better.
The Multinational Corporation and Globalization
MarketsandMarkets Presents Cosmetic Packaging Market worth $32, Million by 2018
Gedeon Richter Ltd. Founded: 1901 Privatised: International locations: 31 Leading position in the region: CIS, EE, Hungary Niche player in the EU.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
The Global LOGISTICS FORUM March 15, Fairmont Bab Al Bahar, Abu Dhabi, UAE Understanding Drivers, Success Factors, Challenges & Enablers of Growing.
Global Demand Driven Research- system solutions Östen Ekengren IVL-Swedish Environmental Research Institute Stockholm Cleantech EUCETSA.
Corporate Presentation INDOCO REMEDIES LTD. About Us Indian Company with an International presence Turnover 09-10; Rs Crores, Turnover 1.
Executive Education in Asia Pacific Acting Dean, HKUST Business School
Global Project Management April 23, 2008 Challenges and Opportunities By Wafa Bunney.
Market Research Report Global and Chinese Zinc dithiophosphateIndustry, Market Research Report.
Why WTO matters for emerging countries? A Brazilian perspective WTO Public Forum Geneva, October 2 nd, 2014.
Career opportunities in medical research. Basic research.
Smart Healthcare- A Journey Creating a Vibrant Debate for a Smart Healthcare Industry Kapil Dev Singh Founder & CEO, Coeus Age Founder & CEO, Core Quadrant.
ACCELLERATING INNOVATION WITH IP ROB WILLOWS VICE PRESIDENT, THOMSON REUTERS CHINA PATENT INFORMATION FAIR SEPTEMBER X, 2011.
China R&D globalization market at USD 7.65 Billion growing at a fast clip, likely to overtake India soon if current-trends continue: Zinnov-Study (1888PressRelease)
© 2017 SlidePlayer.com Inc. All rights reserved.